Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide vs Semaglutide: How the Evidence Compares and What It Means for Your Choice
Why no licensed guidance supports using both at once
Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both approved in the UK for weight management, but they are designed to be used as standalone treatments. Tirzepatide activates both GLP-1 and GIP receptors; semaglutide targets GLP-1 alone. If you are curious whether taking semaglutide and tirzepatide together could amplify results, the short answer is that it does not produce an additive therapeutic effect in the way the pharmacology might superficially suggest, instead, you get overlapping action on the same gastric-emptying and appetite pathways, with substantially higher exposure to the GI side effects both medicines share: nausea, vomiting, diarrhoea and the more serious risk of acute pancreatitis flagged in the MHRA's January 2026 Drug Safety Update for GLP-1 medicines.
Neither the Mounjaro SmPC nor the Wegovy SmPC includes a dosing regimen for co-administration, and NICE's appraisals of both medicines (TA1026 for tirzepatide and TA875 for semaglutide) evaluate each as a monotherapy. There is no trial data on combined use in weight management. A prescriber asked to co-prescribe both would be operating outside the evidence base entirely. That is not a bureaucratic obstacle; it is the honest clinical position.
If you have been on one and are not seeing the results you hoped for, the question worth asking is whether the dose has been optimised, or whether switching is the better move. Our prescribers cover exactly this at consultation, you can explore that through the free consultation page.
How the two medicines compare when used as intended
The most direct evidence comes from the SURMOUNT-5 trial, an open-label head-to-head study published in the New England Journal of Medicine in 2025, involving 751 adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight reduction than semaglutide 2.4mg. SURMOUNT-1 had already shown average body-weight reductions of around 20–21% at tirzepatide's 15mg dose over 72 weeks. The STEP 1 trial for semaglutide 2.4mg, also 68 weeks, showed average reductions of around 15%. The MHRA's approval of a 7.2mg semaglutide dose in April 2026 narrows that gap (trials at the higher dose reported around 20.7% average loss) though it remains a newer data set.
The table below summarises the key factual differences relevant to this comparison.
| Feature | Tirzepatide (Mounjaro) | Semaglutide (Wegovy injection) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Licensed UK doses | 2.5 mg to 15 mg (once weekly) | 0.25 mg to 2.4 mg standard; 7.2 mg available from April 2026 |
| Average weight loss in trials | ~20–21% at 15 mg (SURMOUNT-1, NEJM 2023) | ~15% at 2.4 mg (STEP 1, NEJM 2021); ~20.7% at 7.2 mg |
| Head-to-head result | Greater average loss vs semaglutide 2.4 mg (SURMOUNT-5, NEJM 2025) | 7.2 mg narrows the gap |
| Storage | Refrigerated; room-temp window per the SmPC | Refrigerated; room-temp window per the SmPC |
| NICE recommendation | TA1026 (BMI ≥35 + ≥1 comorbidity, private route: ≥30 per SmPC) | TA875 (specialist services, max 2 years; private route per SmPC) |
For a closer look at how the two compare across cost and availability, the Wegovy vs Mounjaro comparison page covers those angles in detail.
Practical considerations: storage, routine and switching
Both medicines live in the fridge, most patients tuck the pen in the door next to everyday items and inject on the same day each week. Our page on Mounjaro and Wegovy together explains in more detail why they should never be confused with each other in storage or labelling, which is a practical reason (on top of the clinical one) why they are never prescribed together.
Switching from one to the other is a more common scenario than combining them. If tirzepatide is unavailable at a particular dose, or if semaglutide is already established and working well, a prescriber will weigh the clinical picture before suggesting any change. The question of whether to change from Mounjaro to Wegovy depends on tolerability, response and supply, not on a preference for the dual mechanism in the abstract.
A point worth stating clearly: Ozempic is also semaglutide, but it holds a UK licence for type 2 diabetes rather than weight management. It is not interchangeable with Wegovy for this purpose, and it should not feature in any weight-loss comparison as though it were. The semaglutide or tirzepatide guide covers the distinction between the two licensed weight-loss options more fully.
Which medicine is right for you
There is no universal answer. Trial averages are population statistics; individual responses vary considerably. Some people tolerate one medicine's GI profile better than the other's; some have comorbidities or concurrent medicines (oral contraceptives, for example, where tirzepatide's effect on absorption requires an additional contraceptive method for the first four weeks of treatment and after each dose increase) that tip the clinical balance. If you are still weighing up whether you can take Mounjaro and Wegovy together, the NHS England guidance on weight-management injections sets out the broader eligibility framework for both.
At nume, a GPhC-registered Independent Prescriber reviews your full health picture before any treatment is issued. That review covers which medicine is appropriate, the correct starting dose, and whether any interactions or contraindications apply to you specifically. For more on how we approach that process, the about us page explains our clinical model, and our clinical team profile gives the detail behind our prescribing oversight.
Which medicine suits you is a clinical decision our prescribers make with you. The right place to start is a free consultation, where that decision gets made properly.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.